Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms

Leuk Res. 2014 Aug;38(8):896-900. doi: 10.1016/j.leukres.2014.05.015. Epub 2014 Jun 4.

Abstract

Newly emerged clonal cytogenetic abnormalities (CCA) in patients with prior cytotoxic therapy are highly concerning for therapy-related myeloid neoplasms (t-MN). In some patients, however, CCA appeared to be clinically "silent". In this study, we describe 25 patients who developed CCA after they received cytotoxic therapies for lymphoid neoplasms but never developed t-MN. These clinically "silent" CCA were always present as single abnormalities, often detected in a small subset of cells, and tended to disappear over time. We conclude that the occurrence of CCA is not always associated with t-MN. Clinical correlation is essential to guide a proper management of these patients.

Keywords: Bone marrow; Clonal cytogenetic abnormalities; Cytotoxic therapy; Silent; Therapy-related myeloid neoplasms.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Bone Marrow / pathology
  • Child, Preschool
  • Chromosome Aberrations / chemically induced*
  • Cohort Studies
  • Female
  • Humans
  • Leukemia, Myeloid, Acute / chemically induced
  • Lymphoma / drug therapy*
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / chemically induced
  • Neoplasms, Second Primary / chemically induced

Substances

  • Antineoplastic Agents